This discrepancy was attributed to the fact that, although cadonilimab was a bispecific antibody, its clinical benefits were enhanced with higher levels of PD-L1 expression, consistent with its performance in other solid tumors, such as cervical cancer (Wu et al., 2024). This evidence concerns the gene CD274 and cervical cancer.